联康生物科技集团:抗真菌药物上市申请获受理,预计2026年下半年落地

e公司
Jul 21, 2025

联康生物科技集团(00690.HK)公布,公司递交的硫酸艾沙康唑胶囊的上市申请已正式获国家药品监督管理局受理,这是公司在抗真菌治疗领域取得的重要里程碑。硫酸艾沙康唑胶囊预计2026年下半年获批上市,为广大侵袭性真菌感染(例如侵袭性曲霉病和侵袭性毛霉病)患者提供更有效、更安全的高质量治疗选择。据介绍,硫酸艾沙康唑是一款新型三唑类抗真菌药物,具有广谱抗菌活性。其作用机制是通过抑制细胞色素P450,来...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10